MindMedMNMD
MNMD
About: Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Employees: 74
0
Funds holding %
of 7,428 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
33% more call options, than puts
Call options by funds: $4.71M | Put options by funds: $3.53M
13% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 48
12% more capital invested
Capital invested by funds: $240M [Q1] → $270M (+$29.3M) [Q2]
0.47% more ownership
Funds ownership: 54.59% [Q1] → 55.06% (+0.47%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
8% less funds holding
Funds holding: 189 [Q1] → 174 (-15) [Q2]
43% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 28
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
103%
upside
Avg. target
$23
128%
upside
High target
$25
154%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Jay Olson | 154%upside $25 | Outperform Reinstated | 4 Aug 2025 |
Chardan Capital Rudy Li | 103%upside $20 | Buy Maintained | 1 Aug 2025 |
Financial journalist opinion
Based on 6 articles about MNMD published over the past 30 days
Negative
The Motley Fool
2 weeks ago
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today
Mind Medicine (MNMD 1.32%) is a clinical stage biotech company that's aiming to bring psychedelics and other compounds to market as forms of treatments for conditions including generalized anxiety disorder (GAD), major depressive disorder (MDD), and autism spectrum disorder (ASD). The business is still in a pre-revenue state and has a highly uncertain forward performance trajectory, but it's recently garnered an uptick in interest from investors thanks to encouraging clinical trial developments and indications that political and regulatory developments could give the company an easier path to commercialization.
Neutral
Business Wire
2 weeks ago
MindMed Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of (i) options to purchase an aggregate of 425,450 common shares of the Company (the "Options") and (ii) 34,500 performance share units (the “PSUs”) (assuming achievement at ta.
Negative
The Motley Fool
2 weeks ago
1 Reason to Buy MindMed (MNMD)
By their nature, clinical-stage biotech companies can be volatile investments. Even by that standard, MindMed (MNMD 2.59%) is quite a risky play; after all, a key element of its business strategy is to develop brain health medications based on compounds that are illegal on the federal level in the U.S.
Positive
The Motley Fool
3 weeks ago
MindMed (MNMD) Q2 Net Loss Jumps 625%
Mind Medicine (MindMed) (MNMD -7.26%), a biopharmaceutical company developing psychedelic-inspired therapies for brain health disorders, reported its second quarter results on July 31, 2025. The company recorded a GAAP EPS loss of $0.50, wider than analyst expectations of $0.38.
Neutral
Seeking Alpha
3 weeks ago
Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Brandi L. Roberts - Chief Financial Officer Daniel Rollings Karlin - Chief Medical Officer Matthew Wiley - Chief Commercial Officer Robert Barrow - CEO & Director Stephanie Fagan - Chief Corporate Affairs Officer Conference Call Participants Brian Corey Abrahams - RBC Capital Markets Christopher W.
Neutral
Business Wire
3 weeks ago
MindMed Reports Q2 2025 Financial Results and Business Updates
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its second quarter 2025 financial results and provided an update on business highlights. “We continue making significant progress across all three of our pivotal Phase 3 trials evaluating MM120 ODT in GAD and MDD, with ongoing enthusiasm from both trial sites and.
Neutral
Business Wire
1 month ago
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to partic.
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy
Mind Medicine MindMed (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Business Wire
1 month ago
MindMed Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 96,400 common shares of the Company (the "Options"), with effective grant dates of July 7, 2025 and July 14, 2025, depending on the applic.
Positive
Proactive Investors
2 months ago
FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks
The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude towards psychedelic therapies under the Trump administration. Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, unlike full FDA approval, they require a lower standard of evidence, a report from health-oriented news website Stat published on Wednesday highlighted.
Charts implemented using Lightweight Charts™